Compare Nu Holdings Ltd (NU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Twist Bioscience Corp — how do they compare? Nu Holdings Ltd trades at $15 (market cap $74.05B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Nu Holdings Ltd is far larger — about 8.8× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NU | TWST | |
|---|---|---|
Market Cap | $74.05B | $8.42B |
Sector | Financials | Health |
52-Week High | $18.76 | $153.10 |
52-Week Low | $11.60 | $24.16 |
Enterprise Value | — | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings stock trades at $15.33, down slightly by 0.26% today, with a bullish technical signal from moving averages and a consensus analyst price target of $17.20. The company reported strong Q2 2026 results, including a 39% revenue growth and record net income exceeding $1 billion, driven by expanding customer base and AI integration. Cash flow from operations reached $3.5 billion in 2025, supporting robust financial health.
Outlook remains positive with growth opportunities in Mexico and AI-driven efficiencies, but risks include credit quality concerns and competitive pressures. Analysts are predominantly bullish, with 57% recommending buy, though investors should monitor debt levels and macroeconomic factors affecting fintech sectors.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
